Frontlight ResearchEarly access
Triple-negative breast cancer trials in China
133 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2Not yet taking people in ChinaHIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 120
- Run by
- Fudan University
See details and how to joinNCT06849492 - Phase 2Taking peopleQL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Fudan University
See details and how to joinNCT06786026 - No phaseNot yet taking people in ChinaReal-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 300
- Run by
- Fudan University
See details and how to joinNCT06798506 - Phase 2Taking peopleClinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
- Where
- Zhengzhou
- Age
- 18 years to 70 years
- People
- 369
- Run by
- Zhenzhen Liu
See details and how to joinNCT05475678 - Phase 2Taking peopleA Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 160
- Run by
- Mabwell (Shanghai) Bioscience Co., Ltd.
See details and how to joinNCT06492005 - Phase 2Taking peopleAll Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer:a Multi-center, Multi-cohort Phase II Trial
- Where
- Shanghai
- Age
- 18 years and over
- People
- 129
- Run by
- Fudan University
See details and how to joinNCT06636981 - Phase 2Not yet taking people in ChinaJAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 40
- Run by
- Fudan University
See details and how to joinNCT06731153 - Phase 2Not yet taking people in ChinaA Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 120
- Run by
- Tasly Biopharmaceuticals Co., Ltd.
See details and how to joinNCT06724263 - Phase 2Taking peopleSBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
- Where
- Wuhan
- Age
- 18 years and over
- People
- 51
- Run by
- Hubei Cancer Hospital
See details and how to joinNCT06401005 - Phase 2Taking peopleTislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis,an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
- Where
- Hangzhou
- Age
- 18 years to 70 years
- People
- 20
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT06538896 - No phaseTaking peopleDifferent Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
- Where
- Beijing
- People
- 1,166
- Run by
- Shu Wang
See details and how to joinNCT06700382 - No phaseTaking peopleDe-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
- Where
- Beijing
- People
- 380
- Run by
- Peking University People's Hospital
See details and how to joinNCT06692725 - Phase 1/2Taking peopleTIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
- Where
- Beijing
- Age
- 16 years to 90 years
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT06532812 - Phase 3Taking peoplePARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
- Where
- Guangzhou
- Age
- 18 years to 70 years
- People
- 310
- Run by
- Guangdong Provincial People's Hospital
See details and how to joinNCT06533384 - Phase 2Taking peopleLM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 74
- Run by
- Fudan University
See details and how to joinNCT06387628 - Phase 2Taking peopleMilaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- Where
- Hangzhou
- Age
- 18 years to 65 years
- People
- 260
- Run by
- Zhejiang Provincial People's Hospital
See details and how to joinNCT06534762 - Phase 4Taking peopleEffect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
- Where
- Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wenzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou
- Age
- 18 years to 70 years
- People
- 1,072
- Run by
- Fudan University
See details and how to joinNCT04790305 - Early phase 1Taking peopleEGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT05341492 - No phaseTaking peoplea Single-arm, Single-center, Open Clinical Study
- Where
- Zhengzhou
- Age
- 18 years to 75 years
- People
- 10
- Run by
- Beijing Geekgene Technology Co., LTD
See details and how to joinNCT06431100 - Phase 2Not yet taking people in ChinaQL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 73
- Run by
- Fudan University
See details and how to joinNCT06404736 - Phase 2Taking peopleUtidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
- Where
- Changsha
- Age
- 18 years to 70 years
- People
- 53
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT06385990 - Phase 3Taking peopleStudy Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
- Where
- Guangzhou
- Age
- 18 years to 80 years
- People
- 375
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06313463 - Phase 3Taking peopleFamitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 223
- Run by
- Fudan University
See details and how to joinNCT05760378 - Phase 2Not yet taking people in ChinaStudy of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
- Where
- Shenyang
- Age
- 18 years to 75 years
- People
- 128
- Run by
- Shengjing Hospital
See details and how to joinNCT06202313 - Phase 2Taking peopleStereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC
- Where
- Shenyang
- Age
- 18 years to 75 years
- People
- 136
- Run by
- Shengjing Hospital
See details and how to joinNCT06165900